Catherine C. Coombs, MD

Catherine C. Coombs, MD, is a hematologist-oncologist and associate clinical professor in the Department of Medicine of the Division of Hematology/Oncology at University of California Irvine Health.

Articles

Expert Insights on BRUIN CLL-321: Pirtobrutinib in BTKi Pretreated CLL Patients

June 17th 2025

Panelists discuss how the positive BRUIN CLL-321 phase 3 trial results support pirtobrutinib use after covalent BTK inhibitor exposure and consider its role in second-line versus third-line treatment sequencing.

Clinical Approaches in Switching Between BTKi’s in R/R CLL & Practical Considerations for Drug Holidays

June 17th 2025

Panelists discuss how clinical trial data supports switching between different covalent BTK inhibitors for intolerance management, with 60-70% of patients experiencing resolution of the original toxicity.

Identifying BTKi Treatment Intolerance in R/R CLL

June 10th 2025

Panelists discuss how to define true BTK inhibitor intolerance versus manageable side effects and describe successful strategies for switching between covalent BTK inhibitors to maintain treatment efficacy.

Considerations with Retreatment of Venetoclax-Containing Regimens

June 10th 2025

Panelists discuss how retreatment with venetoclax may be appropriate in certain scenarios despite prior exposure, though continuous BTK inhibitor therapy is often preferred for patients with high-risk disease features.

Clinical Perspectives: 59yF with R/R CLL Experiencing BTKi Treatment-Related AE

June 3rd 2025

Panelists discuss how to manage BTK inhibitor-related adverse events including atrial fibrillation, bleeding, and gastrointestinal toxicities through dose modifications, supportive care, and potential drug switching strategies.

Expert Perspectives: Sequencing Strategies after Acalabrutinib + Venetoclax +/- Obinutuzumab as First-Line Therapy in CLL

June 3rd 2025

Panelists discuss how sequencing therapies becomes challenging when using combination regimens like acalabrutinib-venetoclax in frontline treatment, requiring careful consideration of retreatment strategies and resistance mutation testing.

Timing of Treatment Initiation in Relapsed CLL: Factoring in Prognostic and Patient Factors

May 27th 2025

Panelists discuss how they approach prognostic marker testing at relapse, the importance of ruling out Richter's transformation, and timing of treatment initiation based on disease characteristics and progression patterns.

Clinical Perspectives: 59yF with R/R CLL after Time-Limited Therapy

May 27th 2025

Panelists discuss how a CLL patient with initially low-risk disease and mutated IGHV unexpectedly relapsed early after venetoclax-obinutuzumab treatment with acquisition of high-risk features, presenting unique management challenges.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL

March 3rd 2025

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Clinical Pearls and Impacts to Practice from EHA 2024

September 5th 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

August 29th 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

August 29th 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

August 22nd 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

August 22nd 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

August 15th 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

August 15th 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

August 13th 2024

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

August 12th 2024

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

August 12th 2024

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.